Key facts
- It has raised $44.4M; the latest was Early Stage VC ($31.0M) in Oct 2024.
- Notable investors include Innovate UK, Investissement Quebec, Meltwind Advisory, Jonathan Milner, Fonds de solidarite FTQ — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Epitopea
- ·The full record, as it builds
Funding rounds
No funding rounds for Epitopea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epitopea
Developer of transatlantic cancer immunotherapeutics designed to target a novel class of tumor-specific antigens. The company's technology builds on its proprietary approach to identify shared, expressed tumor-specific antigens and develop immunotherapies that are anticipated to kill malignant cells while sparing non-cancerous cells, enabling healthcare providers to cure cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication with minimal side effects and durable benefits.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 46
- Website
- epitopea.com/
- Ownership
- Privately Held (backing)
Epitopea doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epitopea shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epitopea in its N-PORT filings yet. We sweep new filings monthly.